QuantHealth News
5 articlesQuantHealth Appoints Esteemed Pharmaceutical Executives to Inaugural Advisory Board
growth-positive
Accenture invests $2 million in QuantHealth to accelerate use of AI-powered clinical trial simulations | CTech
QuantHealth, an Israeli startup that uses AI to simulate clinical trials, has received a $2 million strategic investment from Accenture Ventures, a leading CRO firm, and other investors. This funding extends QuantHealths recent $15 million Series A round to $17 million. The companys platform, trained on a dataset of 350 million patients, can predict trial outcomes with 86% accuracy. The new capital will be used to enhance this platform. QuantHealth is already working with several global pharmaceutical companies to use its product in clinical trial design and development.
Investment
growth-positive
QuantHealth brings its AI-informed clinical drug trials to the US with $15M round | TechCrunch
QuantHealth, an AI-powered platform for drug discovery, has raised $15 million in a Series A funding round. The platform aims to reduce risks, optimize clinical trials, and predict patient responses to treatment. With an extensive integrated dataset, QuantHealth claims to predict clinical trial outcomes with 86% accuracy. The funding will support the companys trial design solution, expand its platform, and grow its commercial team and operations. The company plans to increase its employee count from 25 to 40 by next year. Bertelsmann Investment and Pitango HealthTech co-led the funding round, with participation from existing backers.
InvestmentExpand
growth-positive
QuantHealth Raises $2.6 Million Seed Round to Provide Comprehensive Clinical Trial Simulation Solution
QuantHealth, an AI-powered clinical trial design startup, has emerged from stealth with a $2.6 million seed financing round. The funding will be used to further develop QuantHealths platform and expand its partnerships with global pharmaceutical companies. The company has built an AI-based clinical trial simulation platform that allows pharmaceutical companies to simulate their upcoming trials and test thousands of protocol variations to maximize the likelihood of success. QuantHealths AI solution is based on a large real-world dataset of over 350 million patients and a biomedical knowledge-graph of over 700,000 biomedical entities and therapeutics. The company has already simulated over 30 trials in oncology and auto-immune diseases with a success rate of over 85%.
InvestmentPartners
growth-positive
4P-Pharma and QuantHealth join forces to conduct AI-based in-Silico clinical trial simulations
4P-Pharma has signed a partnership with QuantHealth, a data science start-up, to conduct in-silico clinical trials of their lead drug candidates. The partnership will begin with the simulation of the phase II clinical trial of 4P004, a disease modifying osteoarthritis drug. The collaboration aims to optimize the success of in-human clinical trials and accelerate the development of first-in-class and best-in-class therapies. 4P-Pharmas translational approach and focus on accelerated clinical development make them an ideal partner for QuantHealths clinical trial simulation platform.
Partners
